ACETAMINOPHEN; IBUPROFEN SODIUM: Pharmaceutical manufacturers, suppliers, and distributors

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Hikma	COMBOGESIC IV	acetaminophen; ibuprofen sodium	SOLUTION;INTRAVENOUS	215320	NDA	Hikma Pharmaceuticals USA Inc.	0143-9150-10	10 VIAL in 1 CARTON (0143-9150-10) / 100 mL in 1 VIAL (0143-9150-01)	2024-02-05
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>NDA/ANDA	>Supplier	>Package Code	>Package	>Marketing Start

Last updated: February 19, 2026

This analysis details the global supply chain for acetaminophen and ibuprofen sodium, focusing on key suppliers, manufacturing capacities, and regulatory landscapes influencing production and availability. The pharmaceutical ingredients market for these analgesics is characterized by a concentration of manufacturers in Asia, particularly China and India, coupled with significant demand driven by their widespread use in over-the-counter and prescription medications.

Who are the Primary Manufacturers of Acetaminophen?

The global supply of acetaminophen (paracetamol) is dominated by a limited number of large-scale manufacturers. These entities control significant production capacity, influencing pricing and availability.

Nantong Jinghua Pharmaceutical Co., Ltd. (China): A major producer of acetaminophen active pharmaceutical ingredient (API). The company has a long history of API manufacturing and exports globally.
Granules India Ltd. (India): A significant player in the global API market, Granules India has substantial manufacturing capacity for acetaminophen. They are a key supplier to both regulated and semi-regulated markets.
Anqiu Luyuan Pharmaceutical Co., Ltd. (China): Another prominent Chinese manufacturer of acetaminophen API. They focus on high-volume production for the international market.
Hubei Xingfa Chemicals Group Co., Ltd. (China): While a diversified chemical company, Xingfa Chemicals has a significant presence in the pharmaceutical intermediates and API sector, including acetaminophen.

These manufacturers operate large-scale facilities designed for efficient, cost-effective production. Production volumes can fluctuate based on global demand, raw material costs, and environmental regulations. For instance, stricter environmental controls in China have, at times, led to temporary production slowdowns or increased operating costs for API manufacturers.

What is the Manufacturing Capacity for Ibuprofen Sodium?

Ibuprofen sodium, a salt form of ibuprofen, shares many manufacturing characteristics with ibuprofen itself. The production of ibuprofen API is concentrated in a few key regions.

BASF SE (Germany): As a major global chemical and pharmaceutical ingredient producer, BASF has significant capacity for ibuprofen API. Their operations are subject to stringent European Union regulations.
IOL Chemicals and Pharmaceuticals Limited (India): IOL is one of the largest producers of ibuprofen API globally. They have expanded their capacity significantly to meet growing demand.
SI Group (United States): SI Group is a key player in the ibuprofen supply chain, focusing on both the API and intermediates. Their manufacturing sites adhere to US Food and Drug Administration (FDA) standards.
Jubilant Life Sciences (India): Jubilant is a diversified pharmaceutical company with substantial API manufacturing capabilities, including ibuprofen.

The production of ibuprofen sodium typically involves the conversion of ibuprofen API into its sodium salt form. This process adds a manufacturing step but leverages the existing ibuprofen API supply chain. Global capacity is estimated to be in the tens of thousands of metric tons annually. Fluctuations in raw material availability, such as the key precursor chemicals needed for ibuprofen synthesis, can impact overall production volumes.

What are the Key Regulatory Considerations for API Suppliers?

Suppliers of acetaminophen and ibuprofen sodium APIs must adhere to a complex web of international and national regulations to ensure product quality, safety, and efficacy.

Good Manufacturing Practices (GMP): All API manufacturers supplying to major regulated markets (e.g., US, EU, Japan) must comply with GMP standards. This includes rigorous quality control, detailed documentation, and process validation. The FDA's cGMP regulations and the European Medicines Agency's (EMA) EudraLex Volume 4 are primary frameworks.
Drug Master Files (DMFs): API manufacturers typically submit DMFs to regulatory authorities like the FDA. A DMF contains confidential, detailed information about the facilities, processes, or articles used in the manufacturing, processing, packaging, and storing of human drugs. This allows drug product manufacturers to reference the API without having direct access to proprietary manufacturing details.
Inspections and Audits: API manufacturing sites are subject to regular inspections by regulatory bodies (e.g., FDA, EMA) and audits by their pharmaceutical clients. Successful audits are critical for market access.
Impurity Control: Regulatory bodies place significant emphasis on controlling impurities in APIs. For acetaminophen, critical impurities include 4-aminophenol (4-AP). For ibuprofen, related substances must be carefully monitored. The ICH Q3A (R2) guideline on impurities in new drug substances is a key reference.
Supply Chain Transparency: There is increasing regulatory pressure for greater transparency throughout the pharmaceutical supply chain, from API sourcing to finished drug product manufacturing.

Non-compliance can lead to warning letters, import alerts, product recalls, and ultimately, the loss of market access. The cost of maintaining GMP compliance, including necessary facility upgrades and quality systems, is a significant factor for API producers.

How Do Raw Material Costs Affect API Pricing?

The pricing of acetaminophen and ibuprofen sodium APIs is directly linked to the cost and availability of key raw materials and intermediates.

Acetaminophen Raw Materials: The primary raw materials for acetaminophen synthesis include phenol, acetic anhydride, and p-aminophenol. Fluctuations in the petrochemical market and the availability of these precursor chemicals can significantly impact acetaminophen API costs. For example, increases in crude oil prices indirectly affect phenol prices.
Ibuprofen Raw Materials: The synthesis of ibuprofen involves several steps, starting with isobutylbenzene and progressing through intermediates like 2-(4-isobutylphenyl)propionic acid. The cost of isobutylbenzene and other reagents is a primary cost driver.

Global supply and demand dynamics for these precursor chemicals, as well as geopolitical events impacting commodity markets, create price volatility. Manufacturers often employ hedging strategies or long-term supply agreements to mitigate these risks. When raw material prices rise, API manufacturers typically pass these increased costs onto their pharmaceutical clients, leading to higher finished drug product costs.

What is the Geographic Concentration of API Production?

The production of acetaminophen and ibuprofen sodium APIs is heavily concentrated in Asia, with China and India being the dominant manufacturing hubs.

China: Holds a substantial share of global API production for both acetaminophen and ibuprofen. This concentration is due to a combination of lower manufacturing costs, established chemical infrastructure, and government support for the pharmaceutical industry. However, environmental regulations and rising labor costs are increasingly influencing production.
India: Is another major global supplier, particularly for ibuprofen. Indian manufacturers have invested heavily in API production capacity and possess strong GMP compliance records, making them key suppliers to regulated markets.

While these two countries dominate, other regions also contribute. European manufacturers like BASF maintain significant production capacity, often focusing on higher-value APIs or serving their regional markets with established quality standards. North American production exists but is generally smaller in scale compared to Asian manufacturing for these high-volume generic APIs.

This geographic concentration presents both opportunities and risks. It allows for economies of scale and cost efficiencies but also creates potential vulnerabilities in the supply chain due to geopolitical instability, natural disasters, or trade disputes.

What are the Key Market Drivers for Acetaminophen and Ibuprofen Sodium?

The demand for acetaminophen and ibuprofen sodium APIs is driven by several fundamental factors:

Widespread Use in Analgesics and Antipyretics: Both drugs are cornerstones of pain and fever management globally. Their availability in over-the-counter (OTC) formulations makes them accessible to vast populations.
Aging Global Population: As the global population ages, the incidence of chronic pain and inflammatory conditions increases, driving sustained demand for pain relievers.
Growing Middle Class in Emerging Markets: Rising disposable incomes in developing economies lead to increased healthcare access and demand for medications, including OTC analgesics.
Cost-Effectiveness: Both acetaminophen and ibuprofen are cost-effective treatments compared to many other therapeutic options, making them preferred choices in many healthcare systems.
Versatility in Formulations: The APIs can be formulated into various dosage forms, including tablets, capsules, liquids, and suppositories, catering to different patient needs and preferences.

The demand for these APIs is generally considered inelastic, meaning that price changes have a relatively small impact on the quantity demanded, given their essential nature. However, sustained shortages or significant price hikes can prompt a search for alternative therapies or increased public health messaging on appropriate usage.

How Do Environmental Regulations Impact API Production?

Environmental regulations are becoming an increasingly significant factor influencing API production, particularly in major manufacturing hubs like China.

Wastewater Treatment and Emissions Control: Chemical synthesis processes for APIs generate wastewater and atmospheric emissions. Manufacturers must invest in advanced treatment facilities to comply with stringent discharge limits for pollutants.
Hazardous Waste Management: The disposal of chemical byproducts and hazardous waste is subject to strict regulations. This adds to operational costs and requires specialized handling and disposal procedures.
Energy Consumption: API manufacturing is energy-intensive. Regulations aimed at reducing carbon emissions and promoting energy efficiency can influence the choice of manufacturing processes and require investments in cleaner technologies.

In China, the government has intensified enforcement of environmental protection laws, leading to temporary plant closures, production curtailments, and increased compliance costs for API manufacturers. This can create supply disruptions and upward pressure on API prices. Companies with robust environmental management systems and efficient production processes are better positioned to navigate these regulatory challenges.

Key Takeaways

The global supply of acetaminophen and ibuprofen sodium APIs is concentrated, with China and India holding dominant positions in manufacturing capacity.
Key suppliers include Nantong Jinghua Pharmaceutical, Granules India, BASF SE, and IOL Chemicals and Pharmaceuticals.
API production is subject to stringent GMP regulations enforced by bodies like the FDA and EMA, requiring significant investment in quality control and documentation.
Raw material costs, driven by petrochemical markets and precursor chemical availability, are a primary determinant of API pricing and can lead to price volatility.
Environmental regulations, particularly in China, are increasingly impacting production costs and potentially causing supply chain disruptions.
Market demand for these APIs remains robust, driven by their widespread use as analgesics and antipyretics, an aging global population, and growing healthcare access in emerging markets.

Frequently Asked Questions

What is the primary difference between acetaminophen and ibuprofen sodium? Acetaminophen is a distinct chemical compound, while ibuprofen sodium is the sodium salt of ibuprofen. Ibuprofen itself is a nonsteroidal anti-inflammatory drug (NSAID), whereas acetaminophen is primarily an analgesic and antipyretic with weaker anti-inflammatory effects. The sodium salt form of ibuprofen can offer different pharmacokinetic properties, such as faster absorption.
Are there single-source API suppliers for acetaminophen or ibuprofen sodium that pose a significant risk? While the market is concentrated among a few major players, there is not typically a single-source supplier for either API. However, reliance on a limited number of large-scale manufacturers in specific geographic regions (e.g., China) presents a concentration risk that could be exacerbated by unforeseen events like trade restrictions or major natural disasters impacting production facilities.
How do batch-to-batch consistency and impurity profiles vary among API suppliers? Reputable API suppliers operating under strict GMP guidelines achieve high levels of batch-to-batch consistency. However, minor variations in impurity profiles can exist due to differences in synthesis routes, raw material sourcing, and process controls. Pharmaceutical companies audit and qualify their API suppliers rigorously to ensure that their chosen API meets the required specifications for purity and consistency.
What is the typical lead time for ordering large quantities of acetaminophen or ibuprofen sodium API from Asian manufacturers? Lead times can vary significantly but typically range from 4 to 12 weeks for large orders, depending on the supplier's current production schedule, raw material availability, and shipping logistics. Urgent or exceptionally large orders may require longer lead times or involve premium pricing.
What are the implications of geopolitical tensions on the supply chain for these APIs? Geopolitical tensions can disrupt supply chains through trade tariffs, export/import restrictions, sanctions, or increased shipping costs and delays. For APIs heavily sourced from specific countries, such tensions can lead to price increases, shortages, and necessitate diversification of sourcing strategies for finished drug product manufacturers.

Citations

[1] U.S. Food and Drug Administration. (n.d.). Current Good Manufacturing Practice (cGMP) Regulations. Retrieved from [FDA Website] (Specific URL for cGMP regulations would be inserted here if available, e.g., https://www.fda.gov/drugs/pharmaceutical-manufacturing/current-good-manufacturing-practice-cgmp-regulations)

[2] European Medicines Agency. (n.d.). EudraLex Volume 4 – GMP guidelines. Retrieved from [EMA Website] (Specific URL for EudraLex Volume 4 would be inserted here if available, e.g., https://www.ema.europa.eu/en/documents/scientific-guideline/eudralex-volume-4-good-manufacturing-practice-principles-manufacturing-active-substances-veterinary-medicinal_en.pdf)

[3] International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. (2003). ICH Harmonised Tripartite Guideline Impurities in New Drug Substances Q3A(R2). Retrieved from [ICH Website] (Specific URL for ICH Q3A(R2) would be inserted here if available, e.g., https://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Quality/Q3A/Q3A_R2_Step_4.pdf)

Suppliers and packagers for generic pharmaceutical drug: ACETAMINOPHEN; IBUPROFEN SODIUM